Equities researchers at StockNews.com initiated coverage on shares of Pulmatrix (NASDAQ:PULM – Get Free Report) in a research note issued to investors on Sunday. The firm set a “hold” rating on the biotechnology company’s stock.
Pulmatrix Stock Down 1.4 %
NASDAQ PULM opened at $2.05 on Friday. The stock has a market capitalization of $7.49 million, a P/E ratio of -0.78 and a beta of 0.99. Pulmatrix has a 52-week low of $1.55 and a 52-week high of $2.75. The firm has a 50-day moving average price of $2.07 and a 200 day moving average price of $2.03.
Pulmatrix (NASDAQ:PULM – Get Free Report) last issued its earnings results on Tuesday, August 13th. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter. The business had revenue of $1.55 million for the quarter. Pulmatrix had a negative return on equity of 46.86% and a negative net margin of 95.18%.
About Pulmatrix
Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Further Reading
- Five stocks we like better than Pulmatrix
- The How and Why of Investing in Gold Stocks
- Airbnb Stock Attracts Attention With Strong Cash Flow Strategy
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- MarketBeat Week in Review – 11/4 – 11/8
- What is a buyback in stocks? A comprehensive guide for investors
- Trump’s Return: Which Sectors Will Benefit Most?
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
